These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 9421870)

  • 1. Optimal three-stage designs for phase II cancer clinical trials.
    Chen TT
    Stat Med; 1997 Dec; 16(23):2701-11. PubMed ID: 9421870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
    Shan G; Zhang H; Jiang T
    BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal flexible designs in phase II clinical trials.
    Chen TT; Ng TH
    Stat Med; 1998 Oct; 17(20):2301-12. PubMed ID: 9819829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An optimal three-stage design for phase II clinical trials.
    Ensign LG; Gehan EA; Kamen DS; Thall PF
    Stat Med; 1994 Sep; 13(17):1727-36. PubMed ID: 7997706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal adaptive two-stage designs for early phase II clinical trials.
    Shan G; Wilding GE; Hutson AD; Gerstenberger S
    Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Admissible two-stage designs for phase II cancer clinical trials.
    Jung SH; Lee T; Kim K; George SL
    Stat Med; 2004 Feb; 23(4):561-9. PubMed ID: 14755389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stochastically curtailed phase II clinical trials.
    Ayanlowo AO; Redden DT
    Stat Med; 2007 Mar; 26(7):1462-72. PubMed ID: 16900560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive two-stage designs in phase II clinical trials.
    Banerjee A; Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal, minimax and admissible two-stage design for phase II oncology clinical trials.
    Qin F; Wu J; Chen F; Wei Y; Zhao Y; Jiang Z; Bai J; Yu H
    BMC Med Res Methodol; 2020 May; 20(1):126. PubMed ID: 32434577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal adaptive two-stage designs for phase II cancer clinical trials.
    Englert S; Kieser M
    Biom J; 2013 Nov; 55(6):955-68. PubMed ID: 23868324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials.
    Kim J; Schell MJ
    Oncotarget; 2019 Jul; 10(42):4255-4261. PubMed ID: 31303960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal futility stopping boundaries for binary endpoints.
    Freitag MM; Li X; Rauch G
    BMC Med Res Methodol; 2024 Mar; 24(1):80. PubMed ID: 38539108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reasonable two-stage adaptive designs for single-arm phase II clinical trials.
    Kashiwabara K; Matsuyama Y
    Pharm Stat; 2018 Nov; 17(6):770-780. PubMed ID: 30168250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graphical search for two-stage designs for phase II clinical trials.
    Jung SH; Carey M; Kim KM
    Control Clin Trials; 2001 Aug; 22(4):367-72. PubMed ID: 11514038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Sample Size Calculation using SAS for PhaseⅡin Two-stage Clinical Trials of Anti-tumor Drugs].
    Li JJ; Hou LS; Zhu P; Du XD; Zhu CR
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 Jul; 48(4):600-604. PubMed ID: 28752982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new adaptive design based on Simon's two-stage optimal design for phase II clinical trials.
    Jin H; Wei Z
    Contemp Clin Trials; 2012 Nov; 33(6):1255-60. PubMed ID: 22772088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multistage designs for phase II clinical trials: statistical issues in cancer research.
    Kramar A; Potvin D; Hill C
    Br J Cancer; 1996 Oct; 74(8):1317-20. PubMed ID: 8883425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical inference for extended or shortened phase II studies based on Simon's two-stage designs.
    Zhao J; Yu M; Feng XP
    BMC Med Res Methodol; 2015 Jun; 15():48. PubMed ID: 26048655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balanced two-stage designs for phase II clinical trials.
    Ye F; Shyr Y
    Clin Trials; 2007; 4(5):514-24. PubMed ID: 17942467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.